POSTERS - IAS

 

2021

Once-daily integrase inhibitor (INSTI) with boosted darunavir is non-inferior to standard of care in virologically suppressed children, Week 48 results of the SMILE PENTA-17 TRIAL; presented at IAS 2021 – the 11th IAS Conference on HIV Science|18-21 JULY 2021
Authors : A. Compagnucci , M. Chan, Y. Saïdi, T. Cressey, A. Bamford, Y. Riault, A. Coelho, A. Nolan, S. Chalermpantmetagul, P. Amuge, V. Musiime, A. Violari, M. Cotton, S. Kanjanavanit, A. Volokha, R. Bologna, N. Pavia Ruz, L. Tato Prieto, P. Paioni, L. Marques, V. Reliquet, S. Welch, D. Ford, C. Giaquinto, D. Gibb, A. Babiker, J.T. Ramos Amador, and the SMILE-PENTA 17 Trial Group. Abstract

Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial; presented at IAS 2021 – the 11th IAS Conference on HIV Science|18-21 JULY 2021
A. Turkova , A. Kekitiinwa, E. White, V. Mumbiro, E. Khauda, A. Liberty, E. Dobbels, G.M. Ahimbisibwe, T. Moloantoa, L. Atwine, S. Kanjanavanit, N.R. Mosia, T. Puthanakit, T. Smit, R. Kobbe, C. Fortuny, E. Chidziva, R.C. Kyambadde, D. Bbuye, T. Sarfati , A. Coelho, Y. Saïdi , A. Lugemwa , N. Klein, M. Bwakura- Dangarembizi, C. Kityo, M. Cotton, C. Giaquinto, P. Rojo, D.M Gibb, D. Ford, the ODYSSEY trial team. Abstract

Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial; presented at IAS 2021 – the 11th IAS Conference on HIV Science|18-21 JULY 2021
A. Turkova, C. Kityo, H.A Mujuru, E. Variava , A. Kekitiinwa, A. Lugemwa, L. Barlow-Mosha, C. Ngampiyaskul, P. Zuidewind, T. Puthanakit, R. Mngqbisa, N.O. Behuhuma, H. Kataike, G. Musoro, A. Nandudu, P. Amuge, S. Makumbi, S. Danaviah, S. Ali, B. Wynne, Y. Riault, S. Welch, T.R Cressey, A. Violari, A. Compagnucci, J. Hakim, P. Rojo, C. Giaquinto, D.M Gibb, D. Ford, the ODYSSEY trial team. Abstract

Effect of dolutegravir on folate and vitamin B12 status among HIV-infected children and adolescents in the ODYSSEY trial; presented at IAS 2021 – the 11th IAS Conference on HIV Science|18-21 JULY 2021
L. Barlow-Mosha *, G. Ahimbisibwe, E. Chappell, P.M. Amuge, A. Nanduudu, E. Kaudha, T. Amukele, D. Balamusani, B. Kafufu, A. Nimwesiga, C. Kityo, A.R Kekitiinwa, R. Namwanje, G. Kasangaki, A. Mulindwa, G.A. Muzorah, D. Bbuye, M. Nolan, C. Giaquinto, D.M Gibb, D. Ford, P. Musoke, A. Turkova, The ODYSSEY Trial Team. Abstract

Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial; presented at IAS 2021 – the 11th IAS Conference on HIV Science|18-21 JULY 2021
C. Kityo *, E. White, A. Turkova, H.A Mujuru, I. Nankya, B. Wynne, S. Ali, A. Kekitiinwa, A. Lugemwa, E. Kaudha, A. Liberty, H. Cassim, M. Archary, M. Cotton, L. Barlow-Mosha, T.R Cressey, C. Ngampiyasakul , U. Srirompotong, O. Behuhuma, Y. Saidi, A. Bamford, R. Kobbe, P. Rojo, C. Giaquinto, D. Gibb, D. Ford. Abstract

A randomised comparison of DTG-based ART vs standard of care in infants and young children living with HIV weighing 3 to 14kg: results from the ODYSSEY trial; presented at IAS 2021 – the 11th IAS Conference on HIV Science|18-21 JULY 2021
A. Lugemwa *, H. Mujuru, B. Wynne, A. Violari, A. Kekitiinwa, C. Kityo, M. Archary, E. Variava , T. Sarfati, C. Shakeshaft, R. Turner, K. Nathoo, E. Chidziva, L. Atwine, N. Ramsagar, A. Liberty , P. Amuge, E. Kaudha, A. Nanduudu, R. Mngqibisa, R. Mosia, M. Cotton, T. Cressey, T. Puthanakit, A. Compagnucci, C. Giaquinto, P. Rojo, D. Ford, D.M Gibb, A. Turkova, ODYSSEY trial team. Abstract

OPTIPRIM 2-ANRS 169 TRIAL COMPARING DOLUTEGRAVIR VS DARUNAVIR IN ACUTE HIV-1 INFECTION; presented at IAS 2021 – the 11th IAS Conference on HIV Science|18-21 JULY 2021
Authors : Antoine Chéret, Rebecca Bauer, Vincent Meiffrédy, Pauline Lopez, Elise Gardiennet, Faïza Ajana, Karine Lacombe, Philippe Morlat, Caroline Lascoux, Jacques Reynes, Gilles Pialoux, Cécile Goujard, Christine Rouzioux , Véronique Avettand-Fenoel, Laurence Meyer.

2018

Anal, oral and genital distribution of HPV in PrEP-users MSM: results at baseline of the ANRS IPERGAY HPV sub-study. 22nd International AIDS conference, Amsterdam, the Netherlands 2018, Abstract TUPEB056.
Authors : Laurent Cotte, David Veyer, Isabelle Charreau, Jean Francois Fléjou, Hélène Péré, Eric Cua, Julie Chas, Isabelle Heard, Constance Delaugerre, Catherine Capitant, Jean-Michel Molina and ANRS IPERGAY Study group.

Is Prevalence of Early HIV-Infection at Baseline Correlated with HIV Incidence: An analysis of 10 PrEP trials. 22nd International AIDS conference, Amsterdam, the Netherlands 2018, Abstract WEPEC 318.
Authors : Antoni G, Pintado C, Delaugerre C, Meyer L, Molina JM.

2017

In Depth Sampling of High Risk Populations to Characterize HIV Transmission Epidemics among Young MSM using PrEP in France and Quebec
Authors:  A. Chaillon, C. Delaugerre, N. Mahjoub, B. Brenner, C. Capitant, D. Carette, M.L. Nere, G.Pialoux, E. Cua, L. Cotte, C. Tremblay, B. Spire, M. Wainberg, C. Goujard, L. Meyer, J.M. Molina, M.L. Chaix

Attitudes about PrEP among physicians who participated in the Open-Label Extension of the ANRS-IPERGAY trial: a qualitative study.
Authors: Marion Di Ciaccio, Marie Suzan-Monti, Christian Chidiac, Camille Bernaud, Antoine Cheret, Gilles Pialoux, Eric Cua, Marine Saouzanet, Emmanuelle Netzer, Bruno Spire, Jean Michel Molina, Marie Préau

Impact of risk perception trajectory on PrEP and condom use among Men who have Sex with Men during the Open-Label-Extension of the ANRS-IPERGAY trial.
Authors: Marion Di Ciaccio, Luis Sagaon-Teyssier, Marie Suzan-Monti, Bakridine Mmadi-mrenda, Eric Cua, Gilles Pialoux, Nicolas Leturque, Valérie Foubert, Marie Préau, Jean Michel Molina, Bruno Spire

Low T cell immunogenicity of the yellow fever vaccine in HIV-infected patients: ANRS EP46 NOVAA
Authors: A. Samri, C. Durier, N. Colin de Verdiere, V. Meiffredy, O. Launay, S. Matheron, S. Mercier-Delarue, A. Boulay, J.-P. Aboulker, J.-M. Molina, F. Simon, B. Autran

First report after early termination of ANRS COV1-COHVAC cohort of healthy volunteers from preventive HIV-1 vaccine trials
Authors: C. Desaint, C. Durier, J.-D. Lelièvre, B. Silbermann, G. Pialoux, L. Cuzin, I. Poizot-Martin, P. Morineau, Z. Sumer-Yalcin, C. Lascoux, A. Bouakane, A. Diallo, J.-P. Aboulker, B. Spire, L. Meyer, O. Launay, COHVAC Study Group, ANRS and Vaccine Research Institute (VRI)